Citation & Authors
Chest. 2026;169(2):428–439.
ABSTRACT · RESEARCH SUMMARY
Research summary
After matching, each group included 1,194 patients with RA-ILD. There was no significant difference in 5-year all-cause mortality (HR 1.073; 95% CI 0.881–1.305), and hospitalization and mechanical ventilation were also similar. However, sensitivity analyses in patients with high baseline inflammatory markers found higher mortality and ventilation risks with tocilizumab. A nonsignificant overall difference does not establish identical efficacy, and the subgroup signals require validation.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
After matching, each group included 1,194 patients. The difference in 5-year all-cause mortality was not statistically significant (HR 1.073; 95% CI 0.881–1.305).
A nonsignificant difference does not establish equivalence. Risk signals in the subgroup with high inflammatory markers should be interpreted alongside the limitations of the original study.
